CIK 0001279704 · Non-accelerated filer<br>Smaller reporting company
Cellectar Biosciences, Inc.
Sign in to watch- Ticker
- CLRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043321804
- Phone
- (608) 441-8120
- Business address
- 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 79 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-24 | NEIS JOHN Director | Grant or award · Stock option (right to buy) | +7,800 | 7,800 | ||
| 2022-06-24 | Loren Stefan Director | Grant or award · Stock option (right to buy) | +7,800 | 7,800 | ||
| 2022-06-24 | DRISCOLL FREDERICK W Director | Grant or award · Stock option (right to buy) | +7,800 | 7,800 | ||
| 2022-06-24 | Chanan-Khan Asher Director | Grant or award · Stock option (right to buy) | +7,800 | 7,800 | ||
| 2022-02-22 | Kolean Chad J Chief Financial Officer | Grant or award · Stock option (right to buy) | +150,000 | 150,000 | ||
| 2022-01-25 | Longcor Jarrod Chief Business Officer | Grant or award · Stock option (right to buy) | +475,000 | 475,000 | ||
| 2022-01-25 | Elefant Dov Chief Financial Officer | Grant or award · Stock option (right to buy) | +422,000 | 422,000 | ||
| 2022-01-25 | CARUSO JAMES V President and CEO | Grant or award · Stock option (right to buy) | +1,419,000 | 1,419,000 | ||
| 2021-09-14 | Swirsky Douglas J Director | Purchase | +25,000 | $1.04 | $26K | 25,000 |
| 2021-09-03 | DRISCOLL FREDERICK W Director | Purchase | +19,417 | $1.04 | $20K | 19,417 |
| 2021-06-30 | Swirsky Douglas J Director | Grant or award · Stock option (right to buy) | +117,000 | 117,000 | ||
| 2021-06-30 | NEIS JOHN Director | Grant or award · Stock option (right to buy) | +78,000 | 78,000 | ||
| 2021-06-30 | Loren Stefan Director | Grant or award · Stock option (right to buy) | +78,000 | 78,000 | ||
| 2021-06-30 | DRISCOLL FREDERICK W Director | Grant or award · Stock option (right to buy) | +78,000 | 78,000 | ||
| 2021-06-30 | Chanan-Khan Asher Director | Grant or award · Stock option (right to buy) | +78,000 | 78,000 | ||
| 2021-03-18 | NEIS JOHN Director | Sale · Series A Warrants | −23,232 | $0.25 | $6K | 0 |
| 2021-03-17 | NEIS JOHN Director | Sale · Series A Warrants | −58,640 | $0.28 | $16K | 23,232 |
| 2021-03-16 | NEIS JOHN Director | Sale · Series A Warrants | −100,515 | $0.31 | $31K | 81,872 |
| 2021-03-15 | NEIS JOHN Director | Sale · Series A Warrants | −11,200 | $0.27 | $3K | 182,387 |
| 2021-03-12 | NEIS JOHN Director | Sale · Series A Warrants | −41,155 | $0.27 | $11K | 193,587 |
Page 4 of 6 · 117 trades